Fox Chase Therapeutics Discovery Inc (formerly known as Fox Chase Chemical Diversity Center) Announces That a New Drug Application Was Submitted to the FDA for Troriluzole by Biohaven Pharmaceuticals
Doylestown, PA. June 5, 2023 – Fox Chase Therapeutics Discovery, Inc. is pleased to announce that a New Drug Application (NDA) was submitted to the U.S. FDA for troriluzole by Biohaven Pharmaceuticals for the treatment of spinocerebellar ataxia type 3 (SCA3). Troriluzole (FC-4157, BVN4157) was designed and prepared at FCTDI (formerly FCCDC) in March, 2015, supported originally by two SBIR grants from the National Institutes of Health (R43CA156781 and R44CA156781).